Atorlip 20: Effective LDL Cholesterol Management for Cardiovascular Health
Atorlip 20
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.47 | $74.00 (0%) | 🛒 Add to cart |
| 60 | $2.22 | $148.00 $133.00 (10%) | 🛒 Add to cart |
| 90 | $2.13 | $222.00 $192.00 (14%) | 🛒 Add to cart |
| 120 | $2.08 | $296.00 $249.00 (16%) | 🛒 Add to cart |
| 180 | $2.04 | $444.00 $367.00 (17%) | 🛒 Add to cart |
| 270 | $2.01
Best per pill | $666.00 $542.00 (19%) | 🛒 Add to cart |
Atorlip 20 contains atorvastatin calcium, a potent HMG-CoA reductase inhibitor specifically formulated to significantly reduce elevated low-density lipoprotein (LDL) cholesterol and triglyceride levels in the blood. This medication is indicated as an adjunct to diet and other therapeutic measures for patients with primary hypercholesterolemia, mixed dyslipidemia, or to reduce the risk of cardiovascular events in high-risk individuals. By competitively inhibiting the hepatic enzyme responsible for cholesterol synthesis, Atorlip 20 promotes the upregulation of LDL receptors, enhancing clearance of atherogenic lipoproteins from the bloodstream. Clinical trials demonstrate its efficacy in slowing the progression of atherosclerosis and reducing the incidence of myocardial infarction and stroke.
Features
- Active ingredient: Atorvastatin calcium 20mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Selective, competitive inhibition of HMG-CoA reductase
- Bioavailability: Approximately 14% due to first-pass metabolism
- Protein binding: ≥98% to plasma proteins
- Elimination half-life: 14 hours; active metabolites up to 30 hours
- Excretion: Primarily hepatic via bile; <2% renal excretion
- Thermostability: Store below 30°C (86°F)
Benefits
- Achieves up to 50% reduction in LDL cholesterol levels with consistent use
- Demonstrates significant reduction in triglyceride concentrations and modest increase in HDL cholesterol
- Proven to reduce the risk of major cardiovascular events, including nonfatal MI and stroke
- Slows progression and may promote regression of coronary atherosclerosis
- Well-tolerated profile with once-daily dosing convenience
- Supported by extensive clinical evidence from landmark studies (ASCOT-LLA, CARDS, TNT)
Common use
Atorlip 20 is primarily prescribed for the management of dyslipidemias, specifically in patients with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia. It is also indicated for cardiovascular risk reduction in patients with type 2 diabetes and other risk factors, as well as for secondary prevention in patients with established cardiovascular disease. The medication is used as part of a comprehensive treatment approach that includes dietary modification, exercise, and management of other cardiovascular risk factors.
Dosage and direction
The recommended starting dose is Atorlip 20 once daily, which may be adjusted based on lipid-lowering response and tolerability. Dosage range is 10-80mg daily, with maximum LDL reduction typically achieved within 2-4 weeks. Administration may occur at any time of day, with or without food, though consistency in timing is recommended. Tablets should be swallowed whole with water and not crushed or chewed. Liver function tests should be performed before initiation and periodically thereafter. Dose adjustments may be necessary in patients taking concomitant cytochrome P450 3A4 inhibitors.
Precautions
Liver enzyme monitoring is essential before starting treatment and periodically thereafter. Patients should report any unexplained muscle pain, tenderness, or weakness immediately, particularly if accompanied by fever or malaise. Use with caution in patients consuming substantial quantities of alcohol or with history of liver disease. May cause elevated HbA1c and fasting serum glucose levels. Ophthalmologic examination is recommended if visual changes occur. Not recommended during pregnancy or in women of childbearing potential not using contraception.
Contraindications
Active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. Hypersensitivity to any component of this medication. Pregnancy, lactation, and women of childbearing age not using adequate contraception. Concomitant use with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, HIV protease inhibitors, or clarithromycin.
Possible side effect
Common adverse reactions (≥2%) include headache, myalgia, arthralgia, diarrhea, nausea, and elevated liver enzymes. Less frequent effects include constipation, flatulence, dyspepsia, and insomnia. Serious but rare side effects include rhabdomyolysis with renal dysfunction, hepatitis, pancreatitis, and peripheral neuropathy. Allergic reactions including rash, pruritus, and angioedema may occur. Cognitive impairment such as memory loss and confusion has been reported.
Drug interaction
Potent CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors) significantly increase atorvastatin exposure. Cyclosporine, gemfibrozil, and niacin may increase risk of myopathy. Concurrent use with warfarin may potentiate anticoagulant effect requiring INR monitoring. Colchicine may increase myopathy risk. Oral contraceptives containing norethindrone and ethinyl estradiol may have increased AUC. Digoxin levels may be slightly increased.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Maintain regular dosing schedule; inconsistent dosing may reduce lipid-lowering efficacy. If multiple doses are missed, consult healthcare provider for guidance on reinitiating therapy.
Overdose
There is no specific antidote for atorvastatin overdose. Suspected overdose should involve supportive measures including gastric lavage if recent ingestion. Monitor for signs and symptoms of myopathy and renal impairment. Liver function tests and CPK levels should be monitored. Hemodialysis is not expected to significantly enhance elimination due to extensive protein binding.
Storage
Store in original container at room temperature (15-30°C or 59-86°F). Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use after expiration date printed on packaging. Do not transfer tablets to other containers as this may affect stability.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient response may vary. Always consult with a qualified healthcare professional before starting or changing any medication regimen. Do not discontinue medication without medical supervision. The prescribing physician should be informed of all concomitant medications and medical conditions.
Reviews
Clinical studies demonstrate Atorlip 20’s consistent efficacy in diverse patient populations. In the ASCOT-LLA trial, atorvastatin 10mg reduced coronary events by 36% in hypertensive patients with additional risk factors. The TNT study showed 80mg provided additional cardiovascular benefit in stable coronary disease patients. Real-world evidence supports its effectiveness in routine clinical practice, with most patients achieving LDL-C targets. Patient satisfaction surveys indicate good tolerability and adherence rates compared to other statins.